Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia

NCT04519125 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

950

Enrollment

OTHER

Sponsor class

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19

Interventions

DRUG: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
OTHER: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)

Sponsor

Hospital Universitario San Ignacio

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]